EGFR Multiplex Mutation Screening Kit
The Atila EGFR Digital PCR Multiplex Mutation Screening Kit identifies 64 possible mutation sites in a single well in a rapid and cost-effective manner, including G719X, Ex19Del, S768I, Ex20Ins, T790M, L858R and L861Q mutation groups.
Each kit includes 100 tests.
CE-IVD Certified. Meets EU standards for safety and performance.
EGFR Multiplex Mutation Screening Kit
The mutations of the epidermal growth factor receptor (EGFR) genes are commonly related with Non-small-cell-lung cancer. Numerous studies have shown that mutations to the EGFR provide the biomarkers that allow more specific cancer treatments, such as tyrosine kinase inhibitors (TKIs). Therefore, it is a critical step towards targeted therapy by identifying the mutations of EGFR with a precise and sensitive method.
Cancer is a genetic disease with uncontrolled growth of abnormal cells. Some types of cancer are frequently associated with specific genetic mutations. Those mutations provide the biomarkers that allow more specific cancer treatments, known as targeted therapy.
Targeted therapy is a newer type of cancer treatment that offers patients the opportunity to use a drug that has a greater effect on cancerous tissue, reducing many of the side effects associated with standard therapy. Therefore, it is a critical step towards targeted therapy by identifying the cancer mutations with a precise and sensitive method.
Features Include
Technical Specs
Workflow Overview for the EGFR Multiplex Mutation Screening Kit
This section is for demonstrative purposes only and may be incomplete or inaccurate. Always refer to the product instructions for precise guidelines and directions.
DNA Extraction
PCR Reaction Assembly
Digital PCR
